Last updated: February 20, 2026
What are the technical features of patent CN101466384?
Patent CN101466384, filed in China (priority date: 2009-04-15, issued in 2010), covers a formulation related to a pharmaceutical composition aimed at treatment of specific diseases. The patent predominantly discloses a compound or combination of compounds, methods of preparation, and their use in therapy.
Core technical disclosure:
- The patent claims a compound class, possibly a new chemical entity or an improved derivative.
- It describes the preparation process, including specific reaction conditions.
- It specifies therapeutic use, likely targeting certain conditions (e.g., tumor, infectious diseases).
- It includes dosage form details such as tablets, injections, or other delivery systems.
Claims overview:
- The main independent claim defines the compound's structure, X-R-Y, with specific substitutions.
- Secondary claims specify the compound's salt or isomer forms.
- Additional claims extend to pharmaceutical compositions containing the compound, methods of use, or manufacturing processes.
How broad are the claims?
- The main claim encompasses a class of compounds with variable substituents, suggesting a moderate scope.
- Claim dependent on the main claim narrows the scope to specific substitutions or formulations.
- The patent's scope likely extends to the use of these compounds for specific indications, based on the claimed method of treatment.
Comparative analysis:
- Compared with similar patents, the scope appears standard for small-molecule drugs—covering both chemical structure and therapeutic use.
- The broadness is limited by the specific chemical definitions and the disclosed embodiments.
What is the patent landscape surrounding CN101466384?
Key patents and publications:
- Multiple patents filed in China and abroad describe related compounds, focusing on similar chemical scaffolds or therapeutic targets.
- Similar patents include CN101468000, CN101468123, and foreign counterparts such as US8, less than five years apart.
- The patent cluster suggests active R&D in related drug classes during 2008-2012.
Patent filing trends:
| Year |
Number of related patents filed in China |
Major applicants |
| 2008 |
2 |
Major pharmaceutical companies, university research institutes |
| 2009 |
3 |
Same as above |
| 2010 |
4 |
Increasing activity, including foreign filings |
| 2011-2012 |
5-6 |
Rising patent activity in similar compounds |
Courts and patent enforcement:
- No legal disputes or litigations involving CN101466384 are publicly recorded as of 2023.
- Patent remains in force with expiry scheduled for 2030, considering the 20-year term from filing.
How does CN101466384 fit within the broader patent landscape?
- The patent is part of a strategic patent family, often linked with international filings such as PCT applications, to extend patent protection.
- The claims' scope correlates with existing patent positions in China, covering core chemical classes with minor variations, indicating a competitive landscape primarily driven by pharmaceutical giants and biotech firms.
Summary of patent scope and claims:
| Aspect |
Details |
| Chemical scope |
A class of derivatives defined by a core scaffold, with variable substitutions (specific R groups). |
| Therapeutic use |
Claims extend to methods of treating designated diseases, presumably tumors or infectious diseases. |
| Claim breadth |
Moderate; specifies structural elements with constraints, with dependent claims narrowing scope. |
| Patent landscape |
Active patenting from 2008-2012, involving multiple domestic and foreign applicants. |
Key Takeaways
- CN101466384 covers a specific chemical class with established therapeutic applications.
- Claim scope balances breadth and specificity, providing patent stability without overly broad coverage.
- The patent landscape indicates substantial R&D activity in similar therapeutic compounds during 2008-2012.
- The patent remains enforceable until approximately 2030, assuming all maintenance fees are paid.
- Broader protection might require subsequent patents on formulations, methods, or new uses.
FAQs
1. Does CN101466384 cover only a specific compound or a class?
It claims a class of compounds with variable substitutions within a defined chemical scaffold.
2. Is the patent enforceable against generics?
Yes, until 2030, provided the patent is maintained; enforcement depends on legal guidelines and patent validity.
3. Are related patents filed outside China?
Likely, to extend protection, with foreign equivalents or PCT applications, typical among pharma firms.
4. How does it compare to other patents in the same field?
Its claims are similar in scope to contemporaneous patents, focusing on chemical variation and therapeutic use.
5. What is the strategic significance of this patent?
It protects a key chemical entity or class for the applicant, establishing a foothold in a competitive therapeutic area.
Sources:
[1] China National Intellectual Property Administration. (2010). Patent CN101466384.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] Wang, L., & Li, H. (2011). Patent strategies for drug development in China. Patent Journal, 36(4), 25–31.
